İbrahim Arslan^1*, Hülya Eyigör1, Kadir Çetin¹, Ömer Tarık Selçuk¹, Serkan Özben², Tomris Özben³ and Hatice Yılmazçoban¹

¹ Antalya Education and Research Hospital, Department of Ear Nose and Throat, Antalya, Turkey
²Antalya Education and Research Hospital, Department of Neurology, Antalya, Turkey
³Akdeniz University Hospital, Department of Medical Biochemistry, Antalya, Turkey

*Corresponding Author: İbrahim Arslan, Antalya Education and Research Hospital, Department of Ear Nose and Throat, Antalya, Turkey.

Received: January 01, 2026; Published: January 29, 2026

Abstract

Objective: Obstructive sleep apnea syndrome (OSAS) is associated with cardiovascular diseases such as hypertension and arrhythmia, metabolic diseases such as diabetes, and cerebrovascular diseases such as thromboembolism. Continuous positive airway pressure (CPAP) is effectively used in the treatment of patients with moderate and severe OSAS. In this study, we aimed to measure serum biomarker levels of nesfatin-1, salusin alpha, salusin beta, and galectin-3 in patients with moderate and severe OSAS, evaluate their relationship with disease severity, and examine the changes in these biomarkers after a long-term CPAP therapy.

Method: A two-center prospective study was performed. A total of 23 patients diagnosed with OSA were included in this study. A control group was formed with 21 healthy volunteers. Serum concentration levels of nesfatin-1, salusin alpha and beta, and galectin-3 were determined using the enzyme-linked immunosorbent assay method. The patients who received CPAP therapy were followed up every three months for one year, and their compliance with treatment was measured using the internal data stores of the CPAP device.

Results: In this study, we found nesfatin-1, salusin alfa, salusin beta and galectin-3 levels were significantly lower in patients with OSAS compared to the healthy controls (p = 0.025, p = 0.049, p = 0.002 and p = 0.043, respectively). There was a statistically significant negative relationship between Apnea-Hipopnea Index (AHI) and the nesfatin-1 levels (p = 0,006). There was also no significant change in biomarker levels among the patients with OSAS before CPAP and after 12 months of therapy (p > 0.05).

Conclusion: The data of our study show a clear negative correlation between nesfatin-1, salusin alfa, salusin beta, galectin-3 levels and OSAS. Furthermore, serum nesfatin-1 levels were negatively correlated with the presence of OSAS and AHI score. Serum nesfatin-1 level may be use of as a new biomarker for early detection and risk assesment of OSAS and its severity. CPAP treatment did not alter levels of these circulating markers.

Keywords: Obstructive Sleep Apnea Syndrome; Continuous Positive Airway Pressure; Nesfatin-1; Salusin Alfa; Salusin Beta; Galectin-3

References

1. Peppard PE., et al. “Increased prevalence of sleep-disordered breathing in adults”. American Journal of Epidemiology 177 (2013): 1006-1014.
2. Peppard PE and Hagen EW. “The last 25 years of obstructive sleep apnea epidemiology and the next 25?” American Journal of Respiratory and Critical Care Medicine 197 (2018): 310-312.
3. Benjafield AV., et al. “Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis”. Lancet Respiratory Medicine 7 (2019): 687-698.
4. Monahan K and Redline S. “Role of obstructive sleep apnea in cardiovascular disease”. Current Opinion on Cardiology 26 (2011): 541-547.
5. Kasai T. “Sleep apnea and heart failure”. Journal of Cardiology 60 (2012): 78-85.
6. Bonsignore MR., et al. “Obstructive sleep apnea and comorbidities: a dangerous liaison”. Multidisciplinary Respiratory Medicine 14 (2019): 8.
7. Kaw R., et al. “Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome”. British Journal of Anaesthesia 109 (2012): 897-906.
8. Dodds S., et al. “Mortality and morbidity in obstructive sleep apnoea-hypopnoea syndrome: results from a 30-year prospective cohort study”. ERJ Open Research 6 (2020): 00057-2020.
9. Miller MA and Cappuccio FP. “A systematic review of COVID-19 and obstructive sleep apnoea”. Sleep Medicine Review 55 (2021): 101382.
10. Gaspar LS., et al. “Obstructive sleep apnea and hallmarks of aging”. Trends in Molecular Medicine 23 (2017): 675-692.
11. Young T., et al. “Epidemiology of obstructive sleep apnea: a population health perspective”. American Journal of Respiratory and Critical Care Medicine 165 (2002): 1217-1239.
12. Félez M., et al. “Increased urinary erythropoietin excretion in severe sleep apnea-hipoapnea syndrome: the effect of CPAP”. Archives of Bronconeumology 54 (2018): 255-259.
13. Hecht L., et al. “Effects of CPAP-respiration on markers of glucose metabolism in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis”. German Medical Science 9 (2011): Doc20.
14. Oh-I S., et al. “Identification of nesfatin-1 as a satiety molecule in the hypothalamus”. Nature 443 (2006): 709-712.
15. Tang CH., et al. “The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain”. Peptides 36 (2012): 39-45.
16. Suzuki N., et al. “Systemic distribution of salusin expression in the rat”. Hypertens Research 30 (2007): 1255-1262.
17. Watanabe T., et al. “A Impact of salusin-α and -ß on human macrophage foam cell formation and coronary atherosclerosis”. Circulation 117 (2008): 638-648.
18. Yokoe T., et al. “Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure”. Circulation 107 (2013): 1129-1134.
19. Kiely JL and McNicholas WT. “Cardiovascular risk factors in patients with obstructive sleep apnoea syndrome”. European Respiratory Journal 16 (2000): 128-133.
20. Punjabi NM., et al. “Sleep-disordered breathing and insulin resistance in middle-aged and overweight men”. American Journal of Respiratory and Critical Care Medicine 165 (2002): 677-682.
21. Mooe T., et al. “Sleep-disordered breathing in men with coronary artery disease”. Chest 109 (1996): 659-663.
22. Sharma UC., et al. “Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction”. Circulation 110 (2004): 3121-3128.
23. Daniels LB., et al. “Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: the Rancho Bernardo Study”. American Heart Journal 167 (2014): 674-682.
24. Jagodzinski A., et al. “Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort”. International Journal of Cardiology192 (2015): 33-39.
25. Djoussé L., et al. “Plasma galectin 3 and heart failure risk in the Physicians' Health Study”. European Journal of Heart Failure 16 (2014): 350-354.
26. Shahar E., et al. “Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study”. American Journal of Respiratory and Critical Care Medicine 163 (2001): 19-25.
27. Cadby G., et al. “Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort”. Chest 148 (2015): 945-952.
28. Gottlieb DJ., et al. “Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study”. Circulation 122 (2010): 352-360.
29. Al-Maghrabi J., et al. “Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas”. Pathology Research Practice 213 (2017): 348-352.
30. Merseburger AS., et al. “Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer”. Prostate 68 (2008): 72-77.
31. Mollenhauer J., et al. “Frequent downregulation of DMBT1 and galectin-3 in epithelial skin cancer”. International Journal of Cancer 105 (2003): 149-157.
32. Jiang SS., et al. “Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma”. Journal of Translation Medicine 12 (2014): 273.
33. Huang Z., et al. “Over expression of galectin-3 associates with short-term poor prognosis in stage II colon cancer”. Cancer Biomark 17 (2016): 445-455.
34. Okda TM., et al. “A novel role of galectin-3 and thyroglobulin in prognosis and differentiation of different stages of thyroid cancer and elucidation of the potential contribution of Bcl-2, IL-8 and TNF-α”. Biomedicines 10 (2022): 352.
35. Kohler M., et al. “Predictors of long-term compliance with continuous positive airway pressure”. Thorax 65 (2010): 829-832.
36. Benedetto M., et al. “Obstructive sleep apnea (OSA): healthcare and social costs”. MedLav 108 (2017): 310-313.
37. Shen P., et al. “Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome”. Sleep Breath 19 (2015): 515-522.
38. Araz O., et al. “Is there a relationship between obstructive sleep apnea syndrome severity and nesfatin-1?” Respiration 90 (2015): 105-110.
39. Shichiri M., et al. “Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities”. Nature Medicine 9 (2003): 1166-1172.
40. Sato K., et al. “Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases”. International Journal of Hypertension 2013 (2013): 965140.
41. Du SL., et al. “Serum salusin-α levels are inversely correlated with the presence and severity of coronary artery disease”. Scandinavian Journal of Clinical and Laboratory Investigation 73 (2013): 339-343.
42. Argüeso P and Panjwani N. “Focus on molecules: galectin-3”. Experimental Eye Research 92 (2011): 2-3.
43. Slouka D., et al. “Biomarkers- a possibility for monitoring of obstructive sleep apnea syndrome”. Neuro Endocrinology Letters 40 (2019): 85-92.
44. Pusuroglu H., et al. “Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity”. Kardiologia Polska 75 (2017): 351-359.
45. Kondratavičienė L., et al. “Changes in left heart geometry, function, and blood serum biomarkers in patients with obstructive sleep apnea after treatment with continuous positive airway pressure”. Medicina (Kaunas) 58 (2022): 1511.

Citation

Citation: İbrahim Arslan., et al. “Selected Biomarkers in Patients with Obstructive Sleep Apnea Syndrome Before and After Continuous Positive Airway Pressure Treatment". Acta Scientific Otolaryngology 8.2 (2026): 11-18.

Copyright

Copyright: © 2026 İbrahim Arslan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.